shutterstock_159488225

Renewed BARDA backing boosts J&J’s COVID-19 vaccine funding by $1bn

pharmafile | November 17, 2020 | News story | Manufacturing and Production, Research and Development BARDA, COVID-19, J&J, JJ, Janssen, Vaccine 

Johnson & Johnson has said that it is injecting around $1 billion of funding into its research efforts to develop a COVID-19 vaccine, part of that sum coming from the US Government.

In an expansion of its current partnership with the Biomedical Advanced Research and Development Authority (BARDA), J&J is set to receive an additional $454 million from the authority to fund its ongoing Phase 3 studies of its adenovirus-based vaccine candidate in a single-dose formulation – a key factor that sets it apart from rival therapies from Moderna and Pfizer and BioNTech.

J&J’s pharmaceutical arm Janssen has also committed to investing $604 million to help fund the trial, which aims to enrol 60,000 participants in total.

This latest cash injection adds to previous investment made by both parties, who both opted to invest equal sums to a total of $1 billion back in March.

J&J also launched its second global COVID-19 vaccine this week. This one, however, will focus on testing the candidate in a two-dose formulation.

Matt Fellows

Related Content

J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer

Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products …

Gilead’s Veklury recommended by NICE for COVID-19 treatment

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

FDA approves J&J’s Opsynvi for PAH treatment

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has …

Latest content